SGN-CD33A

vadastuximab talirine · Seagen Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SGN-CD33A, covering 2018-05-09 to 2018-05-09. Get the full timeline:

Most recent: Clinical Trial Update: A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML [Phase 1]